Recro Pharma Inc (NASDAQ:REPH) investors have a smile on their faces Monday evening, after the drug maker announced that they have entered into an …
Brean Capital analyst Jonathan Aschoff came out with a favorable report on Recro Pharma Inc (NASDAQ:REPH) following several investor meetings with the company’s management. …
Brean Capital’s analyst Jonathan Aschoff came out today with a research note on Recro Pharma Inc (NASDAQ:REPH), maintaining a price target of $26 …
